OK Mer, I see what you are getting at regards the trial numbers....

OK Mer, I see what you are getting at regards the trial numbers. I have ASSUMED that the 4 patients NOT evaluable were the

'additional patients will be added to the third cohort until the current available patients have safely passed the dose limiting window'

referred to in the P1b Trial Recruitment Completion ann of 11-09-2018.

Assumptions are dangerous and, on the available information that I have been able to find, I have unwittingly made one, because nowhere has it been stated that the 4 'unevaluable' patients ALL comprised those additional patients referred to above. [Apologies to Vivo for being so adamant that they were.]

I will email Leslie in an effort to clear this up.